Summary
11.38 -0.17(-1.47%)07/02/2024
Adma Biologics Inc (ADMA)
Adma Biologics Inc (ADMA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.43 | 3.36 | 16.24 | 76.71 | 150.11 | 210.08 | 194.82 | 33.10 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 11.38 | |
| Open | 11.53 | |
| High | 11.68 | |
| Low | 11.34 | |
| Volume | 2,002,869 | |
| Change | -0.17 | |
| Change % | -1.43 | |
| Avg Volume (20 Days) | 2,149,599 | |
| Volume/Avg Volume (20 Days) Ratio | 0.93 | |
| 52 Week Range | 3.06 - 11.68 | |
| Price vs 52 Week High | -2.57% | |
| Price vs 52 Week Low | 271.90% | |
| Range | -1.30 | |
| Gap Up/Down | -0.12 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,643 | |
| EBIDTA | 55,470,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 8.38 | |
| Book Value | 0.6630 | |
| Earnings Per Share | -0.1300 | |
| EPS Estimate Current Quarter | 0.0500 | |
| EPS Estimate Next Quarter | 0.0700 | |
| EPS Estimate Current Year | 0.3000 | |
| EPS Estimate Next Year | 0.5000 | |
| Diluted EPS (TTM) | -0.1300 | |
| Revenues | ||
| Profit Marging | -0.0129 | |
| Operating Marging (TTM) | 0.2665 | |
| Return on asset (TTM) | 0.0851 | |
| Return on equity (TTM) | -0.0243 | |
| Revenue TTM | 283,176,000 | |
| Revenue per share TTM | 1.2550 | |
| Quarterly Revenue Growth (YOY) | 0.4390 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 35,265,157 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 20.7469 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 10.1614 | |
| Revenue Enterprise Value | 5.6695 | |
| EBITDA Enterprise Value | 285.9281 | |
| Shares | ||
| Shares Outstanding | 231,772,000 | |
| Shares Float | 227,198,512 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.04 | |
| Insider (%) | 2.84 | |
| Institutions (%) | 78.01 | |
06/27 10:35 EST - zacks.com
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
06/26 18:55 EST - zacks.com
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Adma Biologics (ADMA) concluded the recent trading session at $10.84, signifying a -1.54% move from its prior day's close.
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Adma Biologics (ADMA) concluded the recent trading session at $10.84, signifying a -1.54% move from its prior day's close.
06/20 18:55 EST - zacks.com
Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know
In the most recent trading session, Adma Biologics (ADMA) closed at $10.71, indicating a +0.85% shift from the previous trading day.
Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know
In the most recent trading session, Adma Biologics (ADMA) closed at $10.71, indicating a +0.85% shift from the previous trading day.
06/11 10:30 EST - zacks.com
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
06/07 14:34 EST - investors.com
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
The top five biotech stocks today have several commonalities. Among them are strong ratings.
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
The top five biotech stocks today have several commonalities. Among them are strong ratings.
06/07 14:34 EST - investors.com
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
06/05 04:38 EST - globenewswire.com
Titanium Metal Market Report 2024: Trends, Analysis and Forecast (2018-2030) Featuring Extensive Profiles of ADMA Products, Precision Castparts, Ametek, Avista, Cristal, and More
Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "Titanium Metal Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering. The global titanium metal market is expected to reach an estimated $2.4 billion by 2030 with a CAGR of 5.8% from 2024 to 2030. The major drivers for this market are rising use of titanium dioxide in the paints & coating industry, growing use of titanium metal in the aerospace & defense industry, as well as, increasing demand for lightweight and fuel-efficient vehicles. The future of the global titanium metal market looks promising with opportunities in the aerospace, industrial, and medical material markets. The study includes a forecast for the global titanium metal by type, application, and region. Titanium Metal Market by Type [Shipment Analysis by Value from 2018 to 2030]:
Titanium Metal Market Report 2024: Trends, Analysis and Forecast (2018-2030) Featuring Extensive Profiles of ADMA Products, Precision Castparts, Ametek, Avista, Cristal, and More
Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "Titanium Metal Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering. The global titanium metal market is expected to reach an estimated $2.4 billion by 2030 with a CAGR of 5.8% from 2024 to 2030. The major drivers for this market are rising use of titanium dioxide in the paints & coating industry, growing use of titanium metal in the aerospace & defense industry, as well as, increasing demand for lightweight and fuel-efficient vehicles. The future of the global titanium metal market looks promising with opportunities in the aerospace, industrial, and medical material markets. The study includes a forecast for the global titanium metal by type, application, and region. Titanium Metal Market by Type [Shipment Analysis by Value from 2018 to 2030]:
05/15 09:06 EST - zacks.com
5 Stocks With Recent Price Strength to Tap May's Rally
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, NTIC, AGS, MBIN, STRA.
5 Stocks With Recent Price Strength to Tap May's Rally
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, NTIC, AGS, MBIN, STRA.
05/13 10:46 EST - zacks.com
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Here is how Adma Biologics (ADMA) and ResMed (RMD) have performed compared to their sector so far this year.
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Here is how Adma Biologics (ADMA) and ResMed (RMD) have performed compared to their sector so far this year.
05/09 23:11 EST - seekingalpha.com
ADMA Biologics, Inc. (ADMA) Q1 2024 Earnings Call Transcript
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 AM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and CEO Brian Lenz - Executive Vice President, Chief Financial Officer and General Manager, ADMA BioCenters Conference Call Participants Anthony Petrone - Mizuho Group Kristen Kluska - Cantor Fitzgerald Gary Nachman - Raymond James Operator Good afternoon, and welcome to the ADMA Biologics First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 09, 2024. At this time, all participants are in a listen-only mode.
ADMA Biologics, Inc. (ADMA) Q1 2024 Earnings Call Transcript
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 AM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and CEO Brian Lenz - Executive Vice President, Chief Financial Officer and General Manager, ADMA BioCenters Conference Call Participants Anthony Petrone - Mizuho Group Kristen Kluska - Cantor Fitzgerald Gary Nachman - Raymond James Operator Good afternoon, and welcome to the ADMA Biologics First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 09, 2024. At this time, all participants are in a listen-only mode.
05/09 19:21 EST - zacks.com
Adma Biologics (ADMA) Surpasses Q1 Earnings and Revenue Estimates
Adma Biologics (ADMA) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to loss of $0.03 per share a year ago.
Adma Biologics (ADMA) Surpasses Q1 Earnings and Revenue Estimates
Adma Biologics (ADMA) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to loss of $0.03 per share a year ago.
05/09 16:05 EST - globenewswire.com
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y 1Q 2024 GAAP Net Income of $17.8 Million, a $24.6 Million Increase Y-o-Y 1Q 2024 Adjusted EBITDA ( 1 ) of $26.4 Million, a 970% Increase Y-o-Y FY 2024 and 2025 Total Revenue Guidance Increased to More Than $355 Million and $410 Million, Respectively FY 2024 Net Income Guidance Increased to More Than $85 Million and Adjusted EBITDA Guidance Increased to More Than $110 Million FY 2025 Net Income Guidance Increased to More than $135 Million and Adjusted EBITDA Guidance Increased to More Than $160 Million Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J.
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y 1Q 2024 GAAP Net Income of $17.8 Million, a $24.6 Million Increase Y-o-Y 1Q 2024 Adjusted EBITDA ( 1 ) of $26.4 Million, a 970% Increase Y-o-Y FY 2024 and 2025 Total Revenue Guidance Increased to More Than $355 Million and $410 Million, Respectively FY 2024 Net Income Guidance Increased to More Than $85 Million and Adjusted EBITDA Guidance Increased to More Than $110 Million FY 2025 Net Income Guidance Increased to More than $135 Million and Adjusted EBITDA Guidance Increased to More Than $160 Million Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J.
05/02 18:51 EST - zacks.com
Adma Biologics (ADMA) Rises Higher Than Market: Key Facts
Adma Biologics (ADMA) reachead $6.74 at the closing of the latest trading day, reflecting a +1.05% change compared to its last close.
Adma Biologics (ADMA) Rises Higher Than Market: Key Facts
Adma Biologics (ADMA) reachead $6.74 at the closing of the latest trading day, reflecting a +1.05% change compared to its last close.
05/02 07:00 EST - globenewswire.com
ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
RAMSEY, N.J. and BOCA RATON, Fla.
ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
RAMSEY, N.J. and BOCA RATON, Fla.
04/30 10:35 EST - zacks.com
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
04/29 12:31 EST - zacks.com
What's in Store for ADMA Biologics (ADMA) in Q1 Earnings?
On ADMA Biologics' (ADMA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
What's in Store for ADMA Biologics (ADMA) in Q1 Earnings?
On ADMA Biologics' (ADMA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
04/28 04:39 EST - seekingalpha.com
3 'Buy-Rated' Biotech Stocks Under $10
Today, we look at three small-cap biotech/biopharma stocks. All three have attractive risk/reward profiles and potential catalysts on the horizon. An investment synopsis on all three firms is presented in the paragraphs below.
3 'Buy-Rated' Biotech Stocks Under $10
Today, we look at three small-cap biotech/biopharma stocks. All three have attractive risk/reward profiles and potential catalysts on the horizon. An investment synopsis on all three firms is presented in the paragraphs below.
04/24 09:51 EST - zacks.com
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
04/19 18:51 EST - zacks.com
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
In the most recent trading session, Adma Biologics (ADMA) closed at $6.27, indicating a +1.13% shift from the previous trading day.
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
In the most recent trading session, Adma Biologics (ADMA) closed at $6.27, indicating a +1.13% shift from the previous trading day.
04/17 18:56 EST - zacks.com
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note
In the most recent trading session, Adma Biologics (ADMA) closed at $6.04, indicating a -1.95% shift from the previous trading day.
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note
In the most recent trading session, Adma Biologics (ADMA) closed at $6.04, indicating a -1.95% shift from the previous trading day.
04/15 07:01 EST - zacks.com
Buy These 4 Low-Beta Stocks to Counter Market Volatility
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Trip.com (TCOM), ADMA Biologics (ADMA), Lantheus (LNTH) and Skyward (SKWD) are well-poised to gain.
Buy These 4 Low-Beta Stocks to Counter Market Volatility
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Trip.com (TCOM), ADMA Biologics (ADMA), Lantheus (LNTH) and Skyward (SKWD) are well-poised to gain.